کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
9112353 1155746 2005 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی علوم غدد
پیش نمایش صفحه اول مقاله
Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies
چکیده انگلیسی
Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. Both insulin resistance and β-cell failure are genetically determined to some extent; however, environmental factors contribute to exacerbate both abnormalities. Type 2 diabetic individuals are also characterised by reduced β-cell mass likely due to increased cellular apoptosis. The early use of insulin therapy in type 2 diabetes may prove beneficial to prevent further β-cell loss and need for exogenous insulin. Treatment options with oral agents are quite diverse, including insulin sensitizers, α-glucosidase inhibitors, and β-cell secretagogues. Although in recent years the emphasis on initial therapy has been shifting from insulin secretagogues to insulin sensitizers such as metformin and thiazolidinediones, questions remain as to genetic and/or phenotypic factors may dictate a different choice of the first antidiabetic drug to be used. It is not totally clear whether monotherapy should be pursued until the maximally effective dose of a given drug or combination therapy should be used to target distinct pathogenic defects in a single patient. Individual phenotypic and genetic characterisation of the patients may help to solve this conundrum, eventually providing tailored treatment algorithms.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Diabetes Research and Clinical Practice - Volume 68, Supplement 1, June 2005, Pages S22-S29
نویسندگان
, , ,